ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

fingolimod

Also written as “Fingolimod”, “FTY720” and “Fingolimod 0.5 mg”.

Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · Renal Insufficiency · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Multiple Sclerosis, Chronic Progressive, led by 4 companies.

Drug pageFingolimod: every studyAll 75 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 7, 201053 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only502 open or runningphase 4since Sep 7, 2010Dec 7, 2004none ahead
Alembic Pharmaceuticalsits history only10 open or runningphase 1since Nov 23, 2015Nov 23, 2015none ahead
Asofarma S.A.I. y C.10 open or runningphase 1since Nov 27, 2018Nov 27, 2018none ahead
Genuine Research Center, Egyptits history only10 open or runningphase 1since Dec 2, 2020Dec 2, 2020none ahead

Also a collaborator on its studies: Hikma Pharmaceuticals, Zenith Technology and Tanabe Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Asofarma S.A.I. y C. only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2018First study: phase 1 study in Healthy VolunteersFirst studyNCT03757338 · 33 enrolled · New Zealand

TargetBeta

“The hydrochloride salt form of fingolimod, an orally available derivate of myriocin and sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) modulator, ”NCIt, by rule
“Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent”ChEMBL 37, by rule

Studies

The one study Asofarma S.A.I. y C. leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03757338Healthy Volunteers · New Zealand1CompletedJan 26, 201633

How it is read

Names in the registry

  • “Fingolimod”, 22 entries
  • “FTY720”, 16 entries
  • “Fingolimod 0.5 mg”, 4 entries
  • “fingolimod”, 4 entries
  • “Fingolimod 1.25 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.